Literature DB >> 22219033

Expression and clinical significance of Notch signaling genes in colorectal cancer.

Hei-Ying Jin1, Hong-Ying Zhang, Xiaofeng Wang, Junhua Xu, Yijing Ding.   

Abstract

The objective of this study was to explore the expression and clinical significance of Notch signaling genes in colorectal cancer. Colorectal cancer samples were prospectively collected from patients post-surgery at the 3rd Affiliated Hospital, Nanjing University of Traditional Chinese Medicine. Immunohistochemistry of tissue arrays was used to analyze the samples and genes involved in the Notch signaling pathway. Microsatellite instability (MSI) was detected by fluorescence multiplex polymerase chain reaction. A total of 146 colorectal cancer samples were collected, including 84 men (57.7%) and 62 women (42.5%). The average age of the study population was 60.8 ± 10.5 years. Notch1 and Notch2 gene expression correlated with tumor pathology type and degree of differentiation. In addition, Jagged 1 (JAG1) and hairy enhancer of split 1 gene expression correlated with the degree of tumor differentiation. Delta-like 1 gene expression varied significantly with tumor location. There was a significant difference between gene expression and MSI. Of the 138 patients, 134 (91.8%) participated in on-site visits, and the average follow-up time was 42.3 ± 13.3 months. During this period, 86 patients (71.6%) were tumor-free. At 1 year post-surgery, 93% of patients were alive, 74% of patients lived for 3 years, and 67% of patients lived for 5 years. The log-rank test was used to perform univariate analysis, and the COX proportional hazards model was used for the multivariate analysis. Based on these analyses, tumor prognosis correlated with the TNM stage, pathological type, microsatellite status as well as Notch2 and JAG1 gene expression. Patients expressing high levels of Notch2 and JAG1 presented with a significantly better prognosis compared to patients expressing negative or weak levels of Notch2 and JAG1. The expression levels of genes associated with the Notch signaling pathway correlated with tumor pathology and the degree of differentiation. In addition, Notch2 and JAG1 expression levels correlated with survival; however, the underlying mechanism for these correlations remains unclear.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22219033     DOI: 10.1007/s13277-011-0301-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  18 in total

Review 1.  Notch signaling: cell fate control and signal integration in development.

Authors:  S Artavanis-Tsakonas; M D Rand; R J Lake
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance.

Authors:  Karisa C Schreck; Pete Taylor; Luigi Marchionni; Vidya Gopalakrishnan; Eli E Bar; Nicholas Gaiano; Charles G Eberhart
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

3.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

Review 4.  The role of Notch in tumorigenesis: oncogene or tumour suppressor?

Authors:  Freddy Radtke; Kenneth Raj
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

5.  Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer.

Authors:  Verónica Rodilla; Alberto Villanueva; Antonia Obrador-Hevia; Alex Robert-Moreno; Vanessa Fernández-Majada; Andrea Grilli; Nuria López-Bigas; Nicolás Bellora; M Mar Albà; Ferran Torres; Mireia Duñach; Xavier Sanjuan; Sara Gonzalez; Thomas Gridley; Gabriel Capella; Anna Bigas; Lluís Espinosa
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-26       Impact factor: 11.205

6.  Integrative genomic analyses on HES/HEY family: Notch-independent HES1, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer.

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Oncol       Date:  2007-08       Impact factor: 5.650

Review 7.  Notch and cancer: a double-edged sword.

Authors:  U Koch; F Radtke
Journal:  Cell Mol Life Sci       Date:  2007-11       Impact factor: 9.261

8.  Control of the reversibility of cellular quiescence by the transcriptional repressor HES1.

Authors:  Liyun Sang; Hilary A Coller; James M Roberts
Journal:  Science       Date:  2008-08-22       Impact factor: 47.728

9.  Complex interplay between β-catenin signalling and Notch effectors in intestinal tumorigenesis.

Authors:  Grégory Peignon; Aurélie Durand; Wulfran Cacheux; Olivier Ayrault; Benoît Terris; Pierre Laurent-Puig; Noah F Shroyer; Isabelle Van Seuningen; Tasuku Honjo; Christine Perret; Béatrice Romagnolo
Journal:  Gut       Date:  2011-02       Impact factor: 23.059

10.  The Notch-2 gene is regulated by Wnt signaling in cultured colorectal cancer cells.

Authors:  Jonas Ungerbäck; Nils Elander; John Grünberg; Mikael Sigvardsson; Peter Söderkvist
Journal:  PLoS One       Date:  2011-03-18       Impact factor: 3.240

View more
  10 in total

1.  Doxorubicin activates the Notch signaling pathway in osteosarcoma.

Authors:  Hongjun Mei; Ling Yu; Peng Ji; Jian Yang; Shuo Fang; Weichun Guo; Yang Liu; Xuanyin Chen
Journal:  Oncol Lett       Date:  2015-04-21       Impact factor: 2.967

2.  Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor.

Authors:  Rui Huang; Guiyu Wang; Yanni Song; Qingchao Tang; Qi You; Zheng Liu; Yinggang Chen; Qian Zhang; Jiaying Li; Shan Muhammand; Xishan Wang
Journal:  Mol Med Rep       Date:  2015-04-28       Impact factor: 2.952

3.  The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer.

Authors:  Yinfang Wu; Lijie Gong; Ji Xu; Yiping Mou; Xiaowu Xu; Zhenyuan Qian
Journal:  Onco Targets Ther       Date:  2017-12-08       Impact factor: 4.147

Review 4.  Inhibition and potential treatment of colorectal cancer by natural compounds via various signaling pathways.

Authors:  Mingchuan Wang; Xianjun Liu; Tong Chen; Xianbin Cheng; Huijie Xiao; Xianglong Meng; Yang Jiang
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

5.  Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling.

Authors:  Heiying Jin; Wei Gong; Chunxia Zhang; Shuiming Wang
Journal:  Onco Targets Ther       Date:  2013-03-08       Impact factor: 4.147

6.  Prognostic value of Notch-1 expression in hepatocellular carcinoma: a meta-analysis.

Authors:  Tao Wu; Min Jiao; Li Jing; Min-Cong Wang; Hai-Feng Sun; Qing Li; Yi-Yang Bai; Yong-Chang Wei; Ke-Jun Nan; Hui Guo
Journal:  Onco Targets Ther       Date:  2015-10-22       Impact factor: 4.147

7.  Identification of potential long non-coding RNA biomarkers associated with the progression of colon cancer.

Authors:  Jingwen Li; Weinan Xue; Junli Lv; Peng Han; Yanlong Liu; Binbin Cui
Journal:  Oncotarget       Date:  2017-05-17

8.  Prognostic value of Notch receptors in postsurgical patients with hepatitis B virus-related hepatocellular carcinoma.

Authors:  Tingdong Yu; Chuangye Han; Guangzhi Zhu; Xiwen Liao; Wei Qin; Chengkun Yang; Zhen Liu; Hao Su; Xiaoguang Liu; Long Yu; Zhengtao Liu; Sicong Lu; Zhiwei Chen; Yu Liang; Jianlu Huang; Xue Qin; Ying Gui; Jiaquan Li; Tao Peng
Journal:  Cancer Med       Date:  2017-05-31       Impact factor: 4.452

9.  Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer.

Authors:  Y Dai; G Wilson; B Huang; M Peng; G Teng; D Zhang; R Zhang; M P A Ebert; J Chen; B C Y Wong; K W Chan; J George; L Qiao
Journal:  Cell Death Dis       Date:  2014-04-10       Impact factor: 8.469

10.  LGR5, HES1 and ATOH1 in Young Rectal Cancer Patients in Egyptian.

Authors:  Heba Morsy; Ahmed Gaballah; Mohamed Samir; Vandrome Nakundi; Mohamed Shamseya; Hanan Mahrous; Abeer Ghazal; Mervat Hashish; Waleed Arafat
Journal:  Asian Pac J Cancer Prev       Date:  2021-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.